Capricor Therapeutics Investors Alert: Join Securities Fraud Class Action Before Deadline

Investor Alert: Join Capricor Therapeutics Class Action

Introduction
Investors who purchased securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025, and July 26, 2026, may find themselves entitled to compensation due to significant losses from alleged securities fraud. The Rosen Law Firm, a leader in investor rights, is urging these investors to act quickly due to an impending deadline for those wishing to serve as lead plaintiffs in a class action lawsuit. The deadline to apply is September 28, 2026.

What Happened?

During the specified class period, investors are claiming that Capricor Therapeutics misled them with materially inaccurate statements concerning its clinical therapy Deramiocel. The company allegedly altered the statistical analysis plan used to analyze critical clinical data, doing so without verifying these changes with the FDA prior to resubmitting their Biologics License Application (BLA). This has raised concerns about the validity of the data presented and the likelihood of regulatory approval for Deramiocel, primarily intended for treating Duchenne muscular dystrophy.

When these discrepancies came to light, investors suffered financial losses as the market reacted to the reality of the situation. Given the complexity and potential implications of this case, many investors have turned to legal action to seek redress for their losses.

Your Next Steps

Investors who believe their rights may have been violated can join the class action without the need for upfront costs, thanks to a contingency fee arrangement. To participate, interested parties can visit Rosen Law Firm's website or call Phillip Kim, Esq. toll-free at 866-767-3653. Email inquiries can also be sent to [email protected].

It is essential to note that while a class action lawsuit has been initiated, no class has been certified yet. Investors have the option of remaining absent as a class member or engaging their own counsel to act on their behalf. Joining as a lead plaintiff involves direct engagement with the court to navigate the lawsuit effectively.

Choosing the Right Legal Representation

Rosen Law Firm emphasizes the importance of selecting qualified legal representation, as many firms may lack the necessary experience in handling securities class actions. The firm has a track record of success in leadership roles, having previously secured the largest settlements in securities class actions against companies. Founding partner Laurence Rosen has received significant recognition in legal circles, including being named a Titan of the Plaintiffs' Bar by Law360.

Conclusion

Investors affected by the alleged fraud at Capricor Therapeutics have a limited window to seek compensation. Engaging in class action litigation could potentially bring about recovery for those who have suffered losses due to misleading statements and corporate irregularities. Make sure to act promptly to preserve your rights and explore your legal options moving forward. Stay updated by following the Rosen Law Firm on LinkedIn, Twitter, and Facebook for the latest information and updates regarding this case.

Contact Information
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel (212) 686-1060
Toll-Free (866) 767-3653
Fax (212) 202-3827
[email protected]
rosenlegal.com